LucksonMathieuMD

Internal Medicine • Cincinnati, OH

Hematology/Oncology

Physician

Join to view full profile

Dr. Mathieu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mathieu's full profile

Already have an account?

Office
234 Goodman St
Mail Location 0796
Cincinnati, OH 45219
Phone+1 513-584-1000

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2006 - 2009
Meharry Medical CollegeClass of 2005

Certifications & Licensure

MD State Medical License 2010 - 2025

Publications & Presentations

PubMed

8 citations
FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.
Luckson N Mathieu, Erin Larkins, Arup K Sinha, Pallavi S Mishra-Kalyani, Samina Jafri
Clinical Cancer Research. 2023-08-15
39 citations
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, Luckson N Mathieu, Yi Ren
Clinical Cancer Research. 2022-06-01
63 citations
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
Luckson Mathieu, Erin Larkins, Oladimeji Akinboro, Pourab Roy, Anup K. Amatya
Clinical Cancer Research. 2021-08-03

Press Mentions

FDA Roundup: September 13, 2024September 13th, 2024
Oncologists Discuss ‘Magic Wand’ Solutions to Improve Clinical Trial DiversityMarch 17th, 2024